ClinicalTrials.gg
CompletedNCT02677116Updated May 20, 2020Results posted

A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer

A Phase 1 interventional study of Olaratumab and Doxorubicin in Neoplasm Metastasis, sponsored by Eli Lilly and Company. Completed at 21 sites in 2 countries. Open to participants aged Up to 17 Years. Per ClinicalTrials.gov, last updated 2020-05-20.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
68
Allocation
Non-randomized
Ages
Up to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies testing doxorubicin in Neoplasm Metastasis — 1 open to participants now, 3 under way, none of them phase 3. Doxorubicin · Neoplasm Metastasis.

Enrollment
7th of 16
68 · median 53
Started
2016
the only one that year
Phase 1
8 of 18
1 open now
Registered
16th of 18
by date
Lead sponsor
1 of 18
Eli Lilly and Company

Among the 18 studies testing doxorubicin in Neoplasm Metastasis, this one is the 7th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2016, is one of 8 in phase 1, and was the 16th registered.

Neoplasm Metastasis

4,046 studies on the registry are indexed under Neoplasm Metastasis; 888 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

1 of the 18 studies testing doxorubicin in Neoplasm Metastasis is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About doxorubicin

Doxorubicin: first FDA approval 1974 (DOXORUBICIN HYDROCHLORIDE), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 689 Neoplasm Metastasis studies recruiting now, 536 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: Up to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing doxorubicin in Neoplasm Metastasis, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the safety of different doses of olaratumab and to determine which dose should be used for future pediatric studies. The present study is open to children with advanced cancer or cancer that has spread to another part of the body. The study has three parts. In the first two parts, a specific dose of olaratumab will be given in 21 day cycles, followed by one of three standard chemotherapy regimens. In the third part, a specific dose of olaratumab will be given with one of three standard chemotherapy regimens in 21 day cycles. Participants will only enroll in one part.

03

Conditions studied

  • Neoplasm Metastasis

Browse trials for

04

Who can participate

Ages eligible
Up to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participant must have histological or cytological evidence of a diagnosis of solid tumor, excluding lymphomas and melanoma, but including central nervous system (CNS) tumors, that is , not be amenable to curative treatment.
  • The participant has the presence of measurable and/or nonmeasurable but evaluable disease as defined by the (RECIST Version 1.1). Response Assessment in Neuro-Oncology (RANO) Criteria or Macdonald Criteria should be used for CNS tumors.
  • The participant has a Lansky (\<16 years of age) or (≥16 years of age) performance score of at least 50.
  • The participant has adequate hematologic, organ, and coagulation function ≤2 weeks (14 days) prior to first dose of study drug:

    • (ANC) ≥750 cubic millimeters (mm³)
    • ≥75,000/mm³
    • ≥8 grams per deciliter (g/dL)
    • Total (sum of conjugated + unconjugated) ≤1.5 x (ULN) for age
    • (ALT) and aspartate aminotransferase (AST) ≤3.0 x ULN
    • Serum creatinine is based on age/gender
    • Adequate coagulation function as defined by ≤1.5 or prothrombin time ≤1.5 x ULN, and partial thromboplastin time ≤1.5 x ULN
  • Both female and male participants of must agree to use highly effective precautions during the trial and up to 3 months following the last dose of olaratumab, or longer for other study drugs according to their label.
  • Participants must have fully recovered from the acute toxic effects of all prior anticancer therapies or must adhere to post-treatment conditions as follows:

    • Myelosuppressive chemotherapy
    • Hematopoietic growth factors
    • Biologic (anti-neoplastic agent)
    • Antibody therapy
    • Radiation
    • Stem cell infusion without traumatic brain injury

Exclusion criteria

Exclusion Criteria:

  • Have received treatment within 21 days of the initial dose of olaratumab with an product or non-approved use of a drug or device or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.
  • Participants that have had bone marrow or solid organ transplant are excluded.
  • The participant has an active fungal, bacterial, and/or known severe viral infection including (HIV) or viral (A, B, or C) hepatitis (screening is not required).
  • Female participants who are pregnant or breastfeeding are excluded.
  • If the participant is to be enrolled in the doxorubicin combination arm, a left ventricular dysfunction ( \< 50%) or shortening fraction of \<27% by echocardiogram (either multigated acquisition [MUGA] or echocardiogram [ECHO] are required, not both).
  • Participants that have received prior anthracycline therapy if the participant is to be enrolled in the doxorubicin combination arm.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
68 participants (actual)

Study arms

  • Experimental
    Olaratumab + Doxorubicin (Part A)

    Cycle 1: Olaratumab 15 mg/kg was administered IV Days 1 and 8. Cycle 2 and beyond: Olaratumab 15 mg/kg administered IV on Days 1 and 8 and doxorubicin administered IV on Days 1 and 2. Treatment will cease when discontinuation criterion is met. All cycles are 21 days.

    Drug: Olaratumab · Drug: Doxorubicin

  • Experimental
    Olaratumab + Vincristine + Irinotecan (Part A)

    Cycle 1: Olaratumab 15 mg/kg was administered IV Days 1 and 8. Cycle 2 and beyond: Olaratumab 15 mg/kg and vincristine administered IV on Days 1 and 8. Irinotecan administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met. All cycles are 21 days.

    Drug: Olaratumab · Drug: Vincristine · Drug: Irinotecan

  • Experimental
    Olaratumab + Ifosfamide (Part A)

    Cycle 1: Olaratumab 15 mg/kg was administered IV Days 1 and 8. Cycle 2 and beyond: Olaratumab 15 mg/kg administered IV on Days 1 and 8 of each cycle. Ifosfamide administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met. All cycles are 21 days.

    Drug: Olaratumab · Drug: Ifosfamide

  • Experimental
    Olaratumab + Doxorubicin (Part B)

    Cycle 1: Olaratumab 20 mg/kg was administered IV Days 1 and 8. Cycle 2 and beyond: Olaratumab 20 mg/kg administered IV on Days 1 and 8 and doxorubicin administered IV on Days 1 and 2. Treatment will cease when discontinuation criterion is met. All cycles are 21 days.

    Drug: Olaratumab · Drug: Doxorubicin

  • Experimental
    Olaratumab + Vincristine + Irinotecan (Part B)

    Cycle 1: Olaratumab 20 mg/kg was administered IV Days 1 and 8. Cycle 2 and beyond: Olaratumab 20 mg/kg and vincristine administered IV on Days 1 and 8. Irinotecan administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met. All cycles are 21 days.

    Drug: Olaratumab · Drug: Vincristine · Drug: Irinotecan

  • Experimental
    Olaratumab + Ifosfamide (Part B)

    Cycle 1: Olaratumab 20 mg/kg was administered IV Days 1 and 8. Cycle 2 and beyond: Olaratumab 20 mg/kg administered IV on Days 1 and 8 of each cycle. Ifosfamide administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met. All cycles are 21 days.

    Drug: Olaratumab · Drug: Doxorubicin · Drug: Ifosfamide

  • Experimental
    Olaratumab + Doxorubicin (Part C)

    Cycle 1 and beyond: Olaratumab 20 mg/kg administered IV on Days 1 and 8 and doxorubicin administered IV on Days 1 and 2. Treatment will cease when discontinuation criterion is met. All cycles are 21 days.

    Drug: Olaratumab · Drug: Doxorubicin

  • Experimental
    Olaratumab + Vincristine + Irinotecan (Part C)

    Cycle 1 and beyond: Olaratumab 20 mg/kg and vincristine administered IV on Days 1 and 8. Irinotecan administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met. All cycles are 21 days.

    Drug: Olaratumab · Drug: Vincristine · Drug: Irinotecan

  • Experimental
    Olaratumab + Ifosfamide (Part C)

    Cycle 1 and beyond: Olaratumab 20 mg/kg administered IV on Days 1 and 8 of each cycle. Ifosfamide administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met. All cycles are 21 days.

    Drug: Olaratumab · Drug: Ifosfamide

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Olaratumab Dose Limiting Toxicities (DLTs)

    A dose limiting toxicity (DLT) was defined as an adverse event (AE) during the first 21 days that was possibly related to the study drug and fulfilled any of the following criteria using the National Cancer Institute's (NCI) Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0: CTCAE Grade 3 nonhematologic toxicity, grade 4 neutropenia that lasted longer than 2 weeks, grade ≥3 thrombocytopenia complicated by hemorrhage, and any hematologic toxicity that caused a cycle delay of \>14 days.

    Time frame: Parts A and B: Cycle 1 through Cycle 2 in each arm (21-day cycle); Part C: Cycle 1 only (21-day cycle)

Secondary outcomes

  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of Olaratumab Part A

    Pharmacokinetics (PK): Maximum serum concentration (Cmax) data of Olaratumab was reported from available sample data.

    Time frame: Cycle 1, Day 8 and Cycle 2, Days 1 and 8: 1.25 hour (h), 2.5 h, 3.5h Postdose

  2. PK: Maximum Concentration (Cmax) of Olaratumab Part B

    PK: Maximum serum concentration (Cmax) data of Olaratumab was reported from available sample data.

    Time frame: Cycle 1, Day 8 and Cycle 2, Days 1 and 8: 1.25 hour (h), 2.5 h, 3.5h Postdose

  3. PK: Maximum Concentration (Cmax) of Olaratumab Part C

    Pharmacokinetics (PK): Maximum serum concentration (Cmax) data of Olaratumab was reported from available sample data.

    Time frame: Cycle 1, Days 1 and 8; Cycle 2, Days 1 and 8: 1.25 hour (h), 2.5 h, 3.5h Postdose

  4. PK: Trough Serum Minimum Concentration (Cmin) of Olaratumab Part A

    PK: Trough serum concentration (Cmin) of Olaratumab was reported. A sample was collected every other cycle from cycles 1, 2, 3-25.

    Time frame: Cycles 1, 2, 3-25; Day 8: 336 Hours Postdose

  5. PK: Trough Serum Minimum Concentration (Cmin) of Olaratumab Part B

    PK: Trough serum concentration (Cmin) of Olaratumab was reported. A sample was collected every other cycle from cycles 1, 2, 3-25.

    Time frame: Cycles 1, 2, 3-25; Day 8: 336 Hours Postdose

  6. PK: Trough Serum Minimum Concentration (Cmin) of Olaratumab Part C

    PK: Trough serum concentration (Cmin) of Olaratumab was reported. A sample was collected every other cycle from cycles 1, 2, 3-25.

    Time frame: Cycles 1, 2, 3-25; Day 8: 336 Hours Postdose

  7. Percentage of Participants With a Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])

    Objective Response Rate (ORR) is the percentage of participants achieving a confirmed best overall tumor response of CR or PR. According to RECIST v1.1, PR defined as a \>30% decrease in the sum of the longest diameters (LD) of the target lesions, taking as reference the baseline sum of the LD; CR was defined as the disappearance of all target and non-target lesions.

    Time frame: Baseline to objective progression or start of new anti-cancer therapy (Up to 7 months)

  8. Progression Free Survival (PFS)

    Progression-free survival (PFS) is defined as the time from baseline to the first date of radiological disease progression or death due to any cause. Progressive disease (PD) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (including the baseline sum if that is the smallest). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeters (mm). The appearance of one or more new lesions is also considered progression. If participant started new treatment before PD, the participant was censored at the date of last tumor assessment prior to new therapy. If treatment was discontinued for reasons other than PD and no further assessment, censoring occurred at last tumor assessment.

    Time frame: Baseline to radiological disease progression or death from any cause (Up to 2 Years)

  9. Percentage of Participants With Treatment Emergent (TE) Positive Anti-Olaratumab Antibodies

    Percentage of participants with a TE positive anti-olaratumab antibodies defined as a participant with a 4-fold (2 dilutions) increase over a positive baseline antibody titer.

    Time frame: From Baseline to Study Completion (Up to 33 Months)

07

Results

Posted May 20, 2020

Participant flow

Participant flow — Overall Study
MilestoneOlaratumab + Vincristine + Irinotecan (Part A)Olaratumab + Doxorubicin (Part A)Olaratumab + Ifosfamide (Part A)Olaratumab + Vincristine + Irinotecan (Part B)Olaratumab + Doxorubicin (Part B)Olaratumab + Ifosfamide (Part B)Olaratumab + Vincristine + Irinotecan (Part C)Olaratumab + Ifosfamide (Part C)Olaratumab + Doxorubicin (Part C)
Started1011910113644
Cycle 1 olaratumab alone1011910113644
Progressive disease776709222
Completed776709222
Not completed343314422
Withdrew: Adverse event010001100
Withdrew: Physician decision023213112
Withdrew: Withdrawal by parent or guardian210100210
Withdrew: Withdrawal by subject100000000

Outcome measures

PrimaryNumber of Participants With Olaratumab Dose Limiting Toxicities (DLTs)

A dose limiting toxicity (DLT) was defined as an adverse event (AE) during the first 21 days that was possibly related to the study drug and fulfilled any of the following criteria using the National Cancer Institute's (NCI) Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0: CTCAE Grade 3 nonhematologic toxicity, grade 4 neutropenia that lasted longer than 2 weeks, grade ≥3 thrombocytopenia complicated by hemorrhage, and any hematologic toxicity that caused a cycle delay of \>14 days.

Time frame:
Parts A and B: Cycle 1 through Cycle 2 in each arm (21-day cycle); Part C: Cycle 1 only (21-day cycle)
Reported as:
Count of participants · Participants
Number of Participants With Olaratumab Dose Limiting Toxicities (DLTs)
ParticipantsOlaratumab + Vincristine + Irinotecan (Part A)Olaratumab + Ifosfamide (Part A)Olaratumab + Doxorubicin (Part A)Olaratumab + Vincristine + Irinotecan (Part B)Olaratumab + Ifosfamide (Part B)Olaratumab + Doxorubicin (Part B)Olaratumab + Vincristine + Irinotecan (Part C)Olaratumab + Ifosfamide (Part C)Olaratumab + Doxorubicin (Part C)
Number of Participants With Olaratumab Dose Limiting Toxicities (DLTs)010101100
SecondaryPharmacokinetics (PK): Maximum Concentration (Cmax) of Olaratumab Part A

Pharmacokinetics (PK): Maximum serum concentration (Cmax) data of Olaratumab was reported from available sample data.

Time frame:
Cycle 1, Day 8 and Cycle 2, Days 1 and 8: 1.25 hour (h), 2.5 h, 3.5h Postdose
Reported as:
Geometric mean · microgram/milliliter (μg/mL)
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Olaratumab Part A
microgram/milliliter (μg/mL)Olaratumab Alone (Part A)Olaratumab + Doxorubicin (Part A)Olaratumab + Ifosfamide (Part A)Olaratumab + Vincristine + Irinotecan (Part A)
Cycle 1, Day 8439 ± 23———
Cycle 2, Day 1—406 ± 21396 ± 39437 ± 44
Cycle 2, Day 8—422 ± 30398 ± 44523 ± 26
SecondaryPK: Maximum Concentration (Cmax) of Olaratumab Part B

PK: Maximum serum concentration (Cmax) data of Olaratumab was reported from available sample data.

Time frame:
Cycle 1, Day 8 and Cycle 2, Days 1 and 8: 1.25 hour (h), 2.5 h, 3.5h Postdose
Reported as:
Geometric mean · microgram/milliliter (μg/mL)
PK: Maximum Concentration (Cmax) of Olaratumab Part B
microgram/milliliter (μg/mL)Olaratumab Alone (Part B)Olaratumab + Doxorubicin (Part B)Olaratumab + Ifosfamide (Part B)Olaratumab +Vincristine + Irinotecan (Part B)
Cycle 1, Day 8639 ± 27———
Cycle 2, Day 1——629 ± 32585 ± 30
Cycle 2, Day 8——696 ± 27647 ± 27
SecondaryPK: Maximum Concentration (Cmax) of Olaratumab Part C

Pharmacokinetics (PK): Maximum serum concentration (Cmax) data of Olaratumab was reported from available sample data.

Time frame:
Cycle 1, Days 1 and 8; Cycle 2, Days 1 and 8: 1.25 hour (h), 2.5 h, 3.5h Postdose
Reported as:
Geometric mean · microgram/milliliter (μg/mL)
PK: Maximum Concentration (Cmax) of Olaratumab Part C
microgram/milliliter (μg/mL)Olaratumab + Doxorubicin Cycle 1 (Part C)Olaratumab + Doxorubicin (Part C)Olaratumab + Vincristine + Irinotecan (Part C)Olaratumab + Ifosfamide (Part C)
Cycle 1, Day 1406 ± 20—548 ± 15363 ± 39
Cycle 1, Day 8493 ± 20—695 ± 37498 ± 43
Cycle 2, Day 8—502 ± 38707 ± 3567 ± 38
SecondaryPK: Trough Serum Minimum Concentration (Cmin) of Olaratumab Part A

PK: Trough serum concentration (Cmin) of Olaratumab was reported. A sample was collected every other cycle from cycles 1, 2, 3-25.

Time frame:
Cycles 1, 2, 3-25; Day 8: 336 Hours Postdose
Reported as:
Geometric mean · μg/mL
PK: Trough Serum Minimum Concentration (Cmin) of Olaratumab Part A
μg/mLOlaratumab Alone (Part A)Olaratumab + Doxorubicin (Part A)Olaratumab + Ifosfamide (Part A)Olaratumab + Vincristine + Irinotecan (Part A)
Cycle 1, Day 873 ± 56—46.3 ± 28497.8 ± 29
Cycle 2, Day 8—38.5 ± 29.1114 ± 8537.7 ± 112
Cycle 3-25, Day 8—94.4 ± 4188.2 ± 7795.1 ± 85
SecondaryPK: Trough Serum Minimum Concentration (Cmin) of Olaratumab Part B

PK: Trough serum concentration (Cmin) of Olaratumab was reported. A sample was collected every other cycle from cycles 1, 2, 3-25.

Time frame:
Cycles 1, 2, 3-25; Day 8: 336 Hours Postdose
Reported as:
Geometric mean · μg/mL
PK: Trough Serum Minimum Concentration (Cmin) of Olaratumab Part B
μg/mLOlaratumab Alone (Part B)Olaratumab + Doxorubicin (Part B)Olaratumab + Ifosfamide (Part B)Olaratumab +Vincristine + Irinotecan (Part B)
Cycle 1, Day 8——125 ± 5599.1 ± 65
Cycle 2, Day 8——199 ± 36230 ± 17
Cycle 3-25, Day 8——289 ± 14348 ± 15
SecondaryPK: Trough Serum Minimum Concentration (Cmin) of Olaratumab Part C

PK: Trough serum concentration (Cmin) of Olaratumab was reported. A sample was collected every other cycle from cycles 1, 2, 3-25.

Time frame:
Cycles 1, 2, 3-25; Day 8: 336 Hours Postdose
Reported as:
Geometric mean · μg/mL
PK: Trough Serum Minimum Concentration (Cmin) of Olaratumab Part C
μg/mLOlaratumab + Doxorubicin (Part C)Olaratumab + Vincristine + Irinotecan (Part C)Olaratumab + Ifosfamide (Part C)
Cycle 1, Day 890.3 ± 3383.7 ± 8124 ± 32
Cycle 2, Day 8141 ± 18134 ± 54NA ± NA
Cycle 3-25, Day 8156 ± 2483.7 ± 48NA ± NA
SecondaryPercentage of Participants With a Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])

Objective Response Rate (ORR) is the percentage of participants achieving a confirmed best overall tumor response of CR or PR. According to RECIST v1.1, PR defined as a \>30% decrease in the sum of the longest diameters (LD) of the target lesions, taking as reference the baseline sum of the LD; CR was defined as the disappearance of all target and non-target lesions.

Time frame:
Baseline to objective progression or start of new anti-cancer therapy (Up to 7 months)
Reported as:
Number · percentage of participants
Percentage of Participants With a Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])
percentage of participantsOlaratumab + Vincristine + Irinotecan (Part A)Olaratumab + Ifosfamide (Part A)Olaratumab + Doxorubicin (Part A)Olaratumab + Vincristine + Irinotecan (Part B)Olaratumab + Ifosfamide (Part B)Olaratumab + Doxorubicin (Part B)Olaratumab + Vincristine + Irinotecan (Part C)Olaratumab + Ifosfamide (Part C)Olaratumab + Doxorubicin (Part C)
Percentage of Participants With a Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])009.120.0000025.0
SecondaryProgression Free Survival (PFS)

Progression-free survival (PFS) is defined as the time from baseline to the first date of radiological disease progression or death due to any cause. Progressive disease (PD) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (including the baseline sum if that is the smallest). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeters (mm). The appearance of one or more new lesions is also considered progression. If participant started new treatment before PD, the participant was censored at the date of last tumor assessment prior to new therapy. If treatment was discontinued for reasons other than PD and no further assessment, censoring occurred at last tumor assessment.

Time frame:
Baseline to radiological disease progression or death from any cause (Up to 2 Years)
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsOlaratumab + Vincristine + Irinotecan (Part A)Olaratumab + Ifosfamide (Part A)Olaratumab + Doxorubicin (Part A)Olaratumab + Vincristine + Irinotecan (Part B)Olaratumab + Ifosfamide (Part B)Olaratumab + Doxorubicin (Part B)Olaratumab + Vincristine + Irinotecan (Part C)Olaratumab + Ifosfamide (Part C)Olaratumab + Doxorubicin (Part C)
Progression Free Survival (PFS)1.54 (0.69 to 15.74)1.38 (0.62 to 5.68)1.26 (0.26 to 5.26)1.28 (0.53 to 11.07)1.25 (1.15 to 3.12)NA (NA to NA)4.07 (1.41 to 4.07)4.88 (0.69 to 8.54)5.52 (1.22 to 5.52)
SecondaryPercentage of Participants With Treatment Emergent (TE) Positive Anti-Olaratumab Antibodies

Percentage of participants with a TE positive anti-olaratumab antibodies defined as a participant with a 4-fold (2 dilutions) increase over a positive baseline antibody titer.

Time frame:
From Baseline to Study Completion (Up to 33 Months)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment Emergent (TE) Positive Anti-Olaratumab Antibodies
percentage of participantsOlaratumab + Vincristine + Irinotecan (Part A)Olaratumab + Ifosfamide (Part A)Olaratumab + Doxorubicin (Part A)Olaratumab + Vincristine + Irinotecan (Part B)Olaratumab + Ifosfamide (Part B)Olaratumab + Doxorubicin (Part B)Olaratumab + Vincristine + Irinotecan (Part C)Olaratumab + Ifosfamide (Part C)Olaratumab + Doxorubicin (Part C)
Percentage of Participants With Treatment Emergent (TE) Positive Anti-Olaratumab Antibodies000000000

Adverse events

Collected over Up to 33 Months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Olaratumab + Vincristine + Irinotecan (Part A)2/10 (20%)3/10 (30%)10/10 (100%)
Olaratumab + Ifosfamide (Part A)1/9 (11.1%)4/9 (44.4%)9/9 (100%)
Olaratumab + Doxorubicin (Part A)2/11 (18.2%)2/11 (18.2%)11/11 (100%)
Olaratumab + Vincristine + Irinotecan (Part B)2/10 (20%)5/10 (50%)9/10 (90%)
Olaratumab + Ifosfamide (Part B)2/13 (15.4%)7/13 (53.8%)13/13 (100%)
Olaratumab + Doxorubicin (Part B)0/1 (0%)0/1 (0%)1/1 (100%)
Olaratumab + Vincristine + Irinotecan (Part C)0/6 (0%)2/6 (33.3%)6/6 (100%)
Olaratumab + Ifosfamide (Part C)0/4 (0%)1/4 (25%)4/4 (100%)
Olaratumab + Doxorubicin (Part C)0/4 (0%)4/4 (100%)4/4 (100%)
Most frequent serious events
Showing 10 of 31
Most frequent serious events
EventOlaratumab + Vincristine + Irinotecan (Part A)Olaratumab + Ifosfamide (Part A)Olaratumab + Doxorubicin (Part A)Olaratumab + Vincristine + Irinotecan (Part B)Olaratumab + Ifosfamide (Part B)Olaratumab + Doxorubicin (Part B)Olaratumab + Vincristine + Irinotecan (Part C)Olaratumab + Ifosfamide (Part C)Olaratumab + Doxorubicin (Part C)
Febrile neutropeniaBlood and lymphatic system disorders0/100/90/111/106/130/11/61/42/4
DiarrhoeaGastrointestinal disorders0/100/90/113/100/130/11/60/40/4
Abdominal infectionInfections and infestations0/100/90/110/100/130/10/60/41/4
Urinary retentionRenal and urinary disorders0/100/90/110/100/130/10/60/41/4
AnaemiaBlood and lymphatic system disorders0/102/90/110/100/130/10/60/40/4
DehydrationMetabolism and nutrition disorders0/100/90/112/100/130/10/60/40/4
Staphylococcus test positiveInvestigations0/100/90/110/100/130/11/60/40/4
Vena cava thrombosisVascular disorders0/100/90/110/100/130/11/60/40/4
Penile infectionInfections and infestations0/61/70/80/40/70/10/20/30/2
Urinary tract infectionInfections and infestations0/101/90/110/100/130/10/60/40/4
Most frequent other events
Showing 10 of 227
Most frequent other events
EventOlaratumab + Vincristine + Irinotecan (Part A)Olaratumab + Ifosfamide (Part A)Olaratumab + Doxorubicin (Part A)Olaratumab + Vincristine + Irinotecan (Part B)Olaratumab + Ifosfamide (Part B)Olaratumab + Doxorubicin (Part B)Olaratumab + Vincristine + Irinotecan (Part C)Olaratumab + Ifosfamide (Part C)Olaratumab + Doxorubicin (Part C)
AnaemiaBlood and lymphatic system disorders4/107/96/115/108/130/14/63/44/4
DiarrhoeaGastrointestinal disorders6/101/91/117/101/130/16/62/41/4
NauseaGastrointestinal disorders5/104/94/117/109/131/12/63/43/4
Alanine aminotransferase increasedInvestigations2/102/91/111/102/131/13/62/40/4
Aspartate aminotransferase increasedInvestigations2/104/91/111/104/131/13/62/40/4
Gamma-glutamyltransferase increasedInvestigations0/104/90/110/100/131/11/61/40/4
ArthralgiaMusculoskeletal and connective tissue disorders2/100/91/111/104/131/11/60/40/4
MyalgiaMusculoskeletal and connective tissue disorders0/100/90/111/100/131/10/61/40/4
Pleural effusionRespiratory, thoracic and mediastinal disorders1/100/91/112/101/131/10/60/40/4
FlushingVascular disorders0/100/90/110/100/131/11/60/40/4

Baseline characteristics

All participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Olaratumab + Vincristine + Irinotecan (Part A)Olaratumab + Doxorubicin (Part A)Olaratumab + Ifosfamide (Part A)Olaratumab + Vincristine + Irinotecan (Part B)Olaratumab + Doxorubicin (Part B)Olaratumab + Ifosfamide (Part B)Olaratumab + Vincristine + Irinotecan (Part C)Olaratumab + Ifosfamide (Part C)Olaratumab + Doxorubicin (Part C)Total
Mean9.9 ± 5.56.8 ± 4.310.7 ± 4.310.6 ± 4.9NA ± NA12.5 ± 3.89.7 ± 5.48.0 ± 7.010.8 ± 5.110.0 ± 4.8
Sex: Female, Male
Sex: Female, Male(Participants)Olaratumab + Vincristine + Irinotecan (Part A)Olaratumab + Doxorubicin (Part A)Olaratumab + Ifosfamide (Part A)Olaratumab + Vincristine + Irinotecan (Part B)Olaratumab + Doxorubicin (Part B)Olaratumab + Ifosfamide (Part B)Olaratumab + Vincristine + Irinotecan (Part C)Olaratumab + Ifosfamide (Part C)Olaratumab + Doxorubicin (Part C)Total
Female43260641228
Male68741723240
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Olaratumab + Vincristine + Irinotecan (Part A)Olaratumab + Doxorubicin (Part A)Olaratumab + Ifosfamide (Part A)Olaratumab + Vincristine + Irinotecan (Part B)Olaratumab + Doxorubicin (Part B)Olaratumab + Ifosfamide (Part B)Olaratumab + Vincristine + Irinotecan (Part C)Olaratumab + Ifosfamide (Part C)Olaratumab + Doxorubicin (Part C)Total
American Indian or Alaska Native0000000000
Asian01100033311
Native Hawaiian or Other Pacific Islander0000000000
Black or African American1122020008
White985711131146
More than one race0000000000
Unknown or Not Reported0111000003
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Olaratumab + Vincristine + Irinotecan (Part A)Olaratumab + Doxorubicin (Part A)Olaratumab + Ifosfamide (Part A)Olaratumab + Vincristine + Irinotecan (Part B)Olaratumab + Doxorubicin (Part B)Olaratumab + Ifosfamide (Part B)Olaratumab + Vincristine + Irinotecan (Part C)Olaratumab + Ifosfamide (Part C)Olaratumab + Doxorubicin (Part C)Total
Hispanic or Latino14110321114
Not Hispanic or Latino977811010043
Not Reported0000001124
Missing0011002217
Region of Enrollment
Region of Enrollment(Participants)Olaratumab + Vincristine + Irinotecan (Part A)Olaratumab + Doxorubicin (Part A)Olaratumab + Ifosfamide (Part A)Olaratumab + Vincristine + Irinotecan (Part B)Olaratumab + Doxorubicin (Part B)Olaratumab + Ifosfamide (Part B)Olaratumab + Vincristine + Irinotecan (Part C)Olaratumab + Ifosfamide (Part C)Olaratumab + Doxorubicin (Part C)Total
United States101191011331159
Japan0000003339
08

Study locations

21 sites
  • Phoenix Childrens Hospital
    Phoenix, Arizona 85016, United States
  • Childrens Hospital of Los Angeles
    Los Angeles, California 90027, United States
  • University of California, San Francisco
    San Francisco, California 94158, United States
  • The Children's Hospital for Cancer and Blood Disorders
    Aurora, Colorado 80045, United States
  • Children's National Medical Center
    Washington, District of Columbia 20010-2970, United States
  • Sylvester Comprehensive Cancer Center
    Miami, Florida 33136, United States
  • Riley Hosptial for Children
    Indianapolis, Indiana 46202, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02115, United States
  • University of Minnesota Medical School
    Minneapolis, Minnesota 55455, United States
  • Children's Mercy Hospital
    Kansas City, Missouri 64108, United States
  • Cohen Children's Medical Center
    New Hyde Park, New York 11040, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Levine Children's Hospital
    Charlotte, North Carolina 28203, United States
  • St Jude Childrens Research Hospital
    Memphis, Tennessee 38105, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232-6307, United States
  • Mary Crowley Cancer Research Center
    Dallas, Texas 75230, United States
  • University of Texas Southwestern Medical Center at Dallas
    Dallas, Texas 75235, United States
  • Texas Childrens Hospital
    Houston, Texas 77030, United States
  • Primary Childrens Medical Center
    Salt Lake City, Utah 84132, United States
  • Seattle Children's Hospital Research Foundation
    Seattle, Washington 98105, United States
  • National Cancer Center Hospital
    Chuo-Ku, Tokyo 104-0045, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2016 to primary completion in Oct 2018, 25 months.

Results were first posted in May 2020, 1 year 7 months after primary completion.

Of 286 industry-sponsored phase 1 interventional studies under Neoplasm Metastasis, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 75. This study's 25 months is below that.

Counting every sponsor, half of 496 studies reached it within 54 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2016
First posted
Feb 9, 2016
StartActual
Aug 29, 2016
Primary completionActual
Oct 10, 2018
CompletionActual
Apr 3, 2019
Results first posted
May 20, 2020
Last update
May 20, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02677116
Responsible party
Sponsor
First posted
Feb 9, 2016
Start date
Aug 29, 2016
Primary completion
Oct 10, 2018
Completion
Apr 3, 2019
Results posted
May 20, 2020
Last update
May 20, 2020

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Doxorubicin · Vincristine · Irinotecan · Ifosfamide

Start the discussion